Bryn Mawr Capital Management Inc’s Haemonetics HAE Stock Holding History

Bryn Mawr Capital Management Inc’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-18,474	Closed	-$597K	–	131
2015 Q3	$597K	Buy	+18,474	New	+$695K	0.1%	211
2014 Q2	–	Sell	-9,900	Closed	-$323K	–	607
2014 Q1	$323K	Buy	+9,900	New	+$378K	0.03%	453
2013 Q4	–	Sell	-10,844	Closed	-$432K	–	574
2013 Q3	$432K	Buy	10,844 +1,320	+14%	+$55.4K	0.03%	354
2013 Q2	$394K	Buy	+9,524	New	+$386K	0.03%	264

Other funds holding HAE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bryn Mawr Capital Management Inc's HAE Position: Q4 2015 in Review

Bryn Mawr Capital Management Inc sold out of Haemonetics (HAE) in Q4 2015, closing a stake of 18,474 shares — an estimated $597K sold.

Bryn Mawr Capital Management Inc first reported a position in HAE in Q2 2013 and held it in 4 quarters. The position peaked at $597K in Q3 2015. 163 funds tracked by Wall St. Rank hold HAE as of Q4 2015.

Bryn Mawr Capital Management Inc reported no remaining Haemonetics position as of Q4 2015 after selling out during the quarter.
Bryn Mawr Capital Management Inc sold 18,474 Haemonetics shares in Q4 2015, an estimated $597K.
Bryn Mawr Capital Management Inc first reported a position in Haemonetics in Q2 2013 and held it in 4 quarters.
Bryn Mawr Capital Management Inc's Haemonetics position peaked at $597K in Q3 2015.
163 funds tracked by Wall St. Rank held Haemonetics as of Q4 2015.

Based on Bryn Mawr Capital Management Inc's 13F filing for Q4 2015.